Business Wire

Women’s Entrepreneurship Accelerator Partners with the WE Empower UN SDG Challenge to Maximize the Development Impact of Women Entrepreneurs

20.11.2021 16:00:00 EET | Business Wire | Press release

Share

The Women’s Entrepreneurship Accelerator (WEA), a strategic multi-partnership convening five United Nations agencies and Mary Kay, Inc., in support of last week Global Entrepreneurship Week and Women’s Entrepreneurship Day, announced a partnership with WE Empower UN SDG challenge, a first-of-its-kind competition for women social entrepreneurs across the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211120005125/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Women’s Entrepreneurship Accelerator Logo (Graphic: WEA)

WEA is designed to maximize the development impact of women entrepreneurship in achieving the UN Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs that fosters growth, sustainability, and resilience. UN Partners of WEA include International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), and UN Women.

The WE Empower UN SDG Challenge is a global business competition for women entrepreneurs who are advancing the UN Sustainable Development Goals and inspiring entire communities to act to create the world they want by 2030. The WE Empower UN SDG Challenge honors women entrepreneurs who are advancing the SDGs through their business practices. The opportunity recognizes their innovative work, ignites awareness about the valuable contribution women entrepreneurs can make toward the SDGs, and provides awardees with capacity-building training sessions and connections with business experts around the world.

The programme elevates and showcases the valuable contributions women entrepreneurs and business leaders can make toward the SDGs and solving the world’s greatest challenges. WE Empower is co-led by Vital Voices and Julie Ann Wrigley Global Futures Laboratory at ASU and supported by partners at Bank of Montréal (BMO), Diane von Furstenberg, the G5 Collective, GroYourBiz, Hawaii Tropical Botanical Garden, Mary Kay, Inc., Oxford University Said Business School, Procter & Gamble, Salesforce, UN Foundation, and the World Bank.

“The WE Empower SDG Challenge powerfully showcases women entrepreneurs as ideal role models demonstrating positive business, social and environmental performance,” said Deborah Gibbins, Chief Operating Officer at Mary Kay, Inc. “The Women’s Entrepreneurship Accelerator is honored to partner with WE Empower, a consortium of over 70 partners joining forces for an even greater multiplied impact.”

“We are thrilled to celebrate our partnership with the Women’s Entrepreneurship Accelerator, co-founded by WE Empower lead partner Mary Kay, Inc.,” said WE Empower UN SDG Challenge co-chair & ASU Julie Ann Wrigley Global Futures Laboratory’s Amanda Ellis. “Women entrepreneurs are valuable solutionaries for the UN SDGs and the global 2030 agenda, and WEA unlocks a suite of valuable support tools to help amplify positive impact.”

Globally, women already comprise one-third of all business owners, making critical economic and social contributions, despite the systemic barriers they face. Only five percent of countries legislate for full gender equality, making the support tools provided by the Women’s Entrepreneurship Accelerator even more important. In June 2021, WEA joined the Generation Equality Forum in Paris as well as the Action Coalition on Economic Justice and Rights, and committed to empower five million women entrepreneurs around the world by 2030 to accelerate progress for gender equality.

During UN General Assembly (UNGA 76), WEA announced the launch of a series of impactful initiatives and knowledge products - all shaped through a gender lens. WEA’s impact work includes digital capacity building tools and training, entrepreneurship and policy research, and gender-responsive procurement (GRP) advocacy and training. In October, WEA also announced a milestone partnership with the Commonwealth Businesswomen’s Network (CBWN) aiming at advancing women entrepreneurship in 54 countries of the Commonwealth.

About the Women’s Entrepreneurship Accelerator
The Women’s Entrepreneurship Accelerator (WEA) is a multi-partnership initiative on women’s entrepreneurship convening 5 UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), UN Women and Mary Kay, Inc. to empower 5 million women entrepreneurs by 2030.

The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.

Learn more at we-accelerate. Follow us: Twitter (@We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)

About WE Empower UN SDG Challenge
The WE Empower UN SDG Challenge is the first-of-its-kind global competition for women social entrepreneurs who are advancing the UN Sustainable Development Goals and inspiring entire communities to act to create the world we want by 2030. The WE Empower Challenge honors innovative women leaders from around the world who are pushing the SDGs forward through sustainable business practices and inspiring others to follow suit. The opportunity recognizes their innovative work and provides Awardees with capacity-building training sessions and opportunities to connect with an unparalleled global network to advance their enterprises. This program elevates and showcases the valuable contribution women entrepreneurs and business leaders can make toward the SDGs and solving the world’s greatest challenges.

About Vital Voices Global Partnership
Vital Voices Global Partnership is an international non-profit organization that identifies and partners with creative and fearless women leaders around the world. Vital Voices searches the world for women leaders with daring vision for change, then works with them to make that vision a reality. We are venture catalysts, who provide leaders with capacity building, skills training, grants, access to a network of their peers, mentorship, visibility, recognition, and guidance to accelerate change on a global scale. For more than 20 years, Vital Voices has invested in over 18,000 women leaders from 182 countries and territories, who have then gone on to create change affecting millions around the world. Vital Voices works with women who advance economic opportunity, increase political and public engagement, end gender-based violence and promote human rights through signature fellowships, individualized investments and meaningful, lifelong partnerships. Vital Voices connects women solving problems in their communities and equips them with the tools they need to incite global, positive change and accelerate shared progress for all. Visit www.vitalvoices.org to learn more.

About Julie Ann Wrigley Global Futures Laboratory at ASU
The Julie Ann Wrigley Global Futures Laboratory at Arizona State University represents the urgent belief that we can and must make a meaningful contribution to ensuring a habitable planet and a future in which well-being is attainable. The Global Futures Laboratory is the world’s first laboratory dedicated to the health of the planet and its inhabitants. It is built upon the deep expertise of ASU and leveraging an extensive network of partners for an ongoing and wide-ranging exchange across all knowledge domains to address the complex social, economic and scientific challenges spawned by the current and future threats from environmental degradation. This platform positions a new world headquarters for an international array of scientists, scholars and innovators and lays the foundation to anticipate and respond to existing and emerging challenges and use innovation to purposefully shape and inform our future. For more information visit globalfutures.asu.edu.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 11:00:00 EET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 11:00:00 EET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 11:00:00 EET | Press release

The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying the foundations for the evolution of AI-supported oncological diagnostics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210610418/en/ On this

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 11:00:00 EET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 10:15:00 EET | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living with NT1. NT1 is a chronic, rare neurological disease caused by a loss of orexin and characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle tone). This results in a spectrum of physical, cognitive and psychosocial effects that can have a debilitating impact on many aspects of a person’s life, including work, education and social interactio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye